- Home
- MESO vs DMLP Comparison
MESO vs DMLP Comparison
Compare MESO & DMLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- DMLP
- Stock Information
- Founded
- MESO 2004
- DMLP 2003
- Country
- MESO Australia
- DMLP United States
- Employees
- MESO N/A
- DMLP N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- DMLP Oil & Gas Production
- Sector
- MESO Health Care
- DMLP Energy
- Exchange
- MESO Nasdaq
- DMLP Nasdaq
- Market Cap
- MESO 1.4B
- DMLP 1.4B
- IPO Year
- MESO N/A
- DMLP N/A
- Fundamental
- Price
- MESO $10.97
- DMLP $27.90
- Analyst Decision
- MESO Buy
- DMLP
- Analyst Count
- MESO 4
- DMLP 0
- Target Price
- MESO $18.00
- DMLP N/A
- AVG Volume (30 Days)
- MESO 156.4K
- DMLP 80.8K
- Earning Date
- MESO 02-26-2025
- DMLP 05-08-2025
- Dividend Yield
- MESO N/A
- DMLP 11.43%
- EPS Growth
- MESO N/A
- DMLP N/A
- EPS
- MESO N/A
- DMLP 2.03
- Revenue
- MESO $5,670,000.00
- DMLP $166,824,000.00
- Revenue This Year
- MESO $152.37
- DMLP N/A
- Revenue Next Year
- MESO $336.12
- DMLP N/A
- P/E Ratio
- MESO N/A
- DMLP $13.69
- Revenue Growth
- MESO N/A
- DMLP 12.09
- 52 Week Low
- MESO $5.78
- DMLP $25.84
- 52 Week High
- MESO $22.00
- DMLP $34.88
- Technical
- Relative Strength Index (RSI)
- MESO 44.34
- DMLP 43.43
- Support Level
- MESO $10.77
- DMLP $26.97
- Resistance Level
- MESO $11.61
- DMLP $28.30
- Average True Range (ATR)
- MESO 0.47
- DMLP 0.71
- MACD
- MESO 0.09
- DMLP -0.10
- Stochastic Oscillator
- MESO 27.68
- DMLP 31.21
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.